After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Dexcom’s continuous blood glucose monitoring systems help people living with diabetes track their blood sugar levels. The device connects to a person’s skin and provides continuous feedback to an app ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results